Inferior outcomes of European vs. US patients with R/R LBCL after CD19 CAR-T cell therapy
8 months ago
[{"url":"https://i.ytimg.com/vi/vLQsYGRD6lA/hq720.jpg?sqp=-oaymwEcCOgCEMoBSFXyq4qpAw4IARUAAIhCGAFwAcABBg==&rs=AOn4CLBjMGJflttT8AuGCLQiBGMvqu9_vw","width":360,"height":202},{"url":"https://i.ytimg.com/vi/vLQsYGRD6lA/hq720.jpg?sqp=-oaymwEcCNAFEJQDSFXyq4qpAw4IARUAAIhCGAFwAcABBg==&rs=AOn4CLDzsKowGjNFJmWq6CN-m9S_RW302w","width":720,"height":404}]
{"url":"https://i.ytimg.com/an_webp/vLQsYGRD6lA/mqdefault_6s.webp?du=3000&sqp=CMCBsakG&rs=AOn4CLDTyyKRkjpZaSIl8E2QXc5RN9q3Hw","width":320,"height":180}
[{"text":"Veit Buecklein, MD, LMU Munich, Munich, Germany, comments on real-world evidence comparing CD19 CAR-T cell therapy\u00a0..."}]
{"name":"VJHemOnc \u2013 Video Journal of Hematological Oncology","id":"UCsQXL4_zTA-FoG9RA1tEGiw","thumbnails":[{"url":"https://yt3.ggpht.com/tLfkaYbACnFuAto-jU_XMyorvysy280aW3Kj1oDAKOH7nd58XYlz5rEL24x9ScNjruMr2YYw9w=s68-c-k-c0x00ffffff-no-rj","width":68,"height":68}],"link":"https://www.youtube.com/channel/UCsQXL4_zTA-FoG9RA1tEGiw"}
{"title":"Inferior outcomes of European vs. US patients with R/R LBCL after CD19 CAR-T cell therapy by VJHemOnc \u2013 Video Journal of Hematological Oncology 96 views 8 months ago 5 minutes, 32 seconds","duration":"5 minutes, 32 seconds"}